Emily Love
Optometrist · Atlanta, GANPI 1215319165
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,940 of the $34,635 with a category attached, or 69.1%. Dompe US, Inc. accounts for 83.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $16,445 and has fallen 99.8% since, to $28 in 2025. Among optometrist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $153.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$29K
- Shire North American Group Inc$1K
- AbbVie$831
- Glaukos Corporation$710
- Sun Pharmaceutical Industries Inc.$453
- Bausch & Lomb Americas Inc.$451
- plus $2K from 16 others
What the payments were for
- Consulting fees$6902%
- Speaking & faculty fees$23,94069%
- Travel & lodging$3,42010%
- Food & beverage$6,43519%
- Education$360%
- Entertainment$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 76 | $28,773 |
| Shire North American Group Inc | 13 | $1,071 |
| AbbVie(2 entities) | 34 | $831 |
| Glaukos Corporation | 7 | $710 |
| Sun Pharmaceutical Industries Inc. | 11 | $453 |
| Bausch & Lomb Americas Inc. | 16 | $451 |
| Novartis | 16 | $427 |
| Alcon | 8 | $408 |
| Oyster Point Pharma, Inc. | 12 | $342 |
| Sight Sciences, Inc. | 8 | $212 |
| Kala Pharmaceuticals, Inc. | 5 | $172 |
| Johnson & Johnson Vision Care, Inc. | 3 | $165 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $165 |
| Amgen(2 entities) | 5 | $123 |
| Optos, Inc. | 1 | $115 |
| Coopervision Inc. | 1 | $102 |
| Biotissue Holdings Inc. | 2 | $46 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Harrow Eye, LLC | 1 | $16 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
| Maculogix, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$27,711
- XIIDRA$924
- CEQUA$328
- LUMIGAN$246
- PANORAMIC OPHTHALMOSCOPE$229
- OCT OPHTHALMOSCOPE$229
- iStent Trabecular Micro-Bypass System Model iS3$180
- iStent inject W$142
- TYRVAYA$138
- Acuvue$132
- RESTASIS$125
- LOTEMAX SM$125
- EYSUVIS$124
- NFC-700$115
- MIEBO$109
- MiSight Contact Lens$102
- INFUSE$101
How this compares
$34,635 in reported general payments places this provider in the 95th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 42 | $22,694 |
| XiidraLifitegrast | 14 | $20,450 |
| RestasisCyclosporine | 14 | $13,666 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $5,256 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $4,808 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 92 | $1,480 |
| Latanoprost | 57 | $604 |
| Prednisolone Acetate | 27 | $603 |
| Timolol Maleate | 32 | $167 |
| ErythromycinErythromycin Base | 18 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $831 | $41,16972 claims |
| Bausch & Lomb Americas Inc.Xiidra | $451 | $20,45014 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $12 | $5,25612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Atlanta
- Joshua JohnstonAtlanta$993K
- Amber ZaunbrecherAtlanta$99K
- Carla AndersonAtlanta$29K
- Sarah FlanaganAtlanta$21K
- Anisha HajiAtlanta$19K
- Anar MauryaAtlanta$18K
- Jonathan ChenAtlanta$15K
- Heer VaishnavAtlanta$14K
- Mohammad AljabiAtlanta$13K
- Soo Jung LeeAtlanta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.